Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

1. Sex- and genotype-dependent nicotine plus cue-primed reinstatement is enhanced in adolescent Sprague Dawley rats containing the humanFrontiers in psychiatry · 2022
   Article
2. Nicotinic receptor antagonists as treatments for nicotine abuse.Advances in pharmacology (San Diego, Calif.) · 2014
   Review
3. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.Biochemical pharmacology · 2013
   Review
4. Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.Biochemical pharmacology · 2013
   Article
5. Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.Frontiers in neuroscience · 2013
   Article
6. Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.Bioorganic & medicinal chemistry letters · 2010
   Article
7. Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release.Bioorganic & medicinal chemistry letters · 2010
   Article
8. The motivational impact of nicotine and its role in tobacco use: final comments and priorities.Nebraska Symposium on Motivation. Nebraska Symposium on Motivation · 2009
   Article
9. Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors at 2 institutions in 2 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as